Clinical Trial Update: A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis [Phase 2]

View source ↗

Summary

Phase 2 trial of cedirogant (ABBV-157) in adults with moderate to severe psoriasis was terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• cedirogant (CEDIROGANT)

Snippet

Sponsor: AbbVie | Conditions: Psoriasis | Phase 2 | Status: TERMINATED | Results posted: 2023-11-29